So the idea is to allow more flexibility. In that way, advanced therapeutic products can be approved more quickly. They'll be entered in the right category later on during the approval process.
On May 6th, 2019. See this statement in context.
On May 6th, 2019. See this statement in context.
Pierre-Luc Dusseault NDP Sherbrooke, QC
So the idea is to allow more flexibility. In that way, advanced therapeutic products can be approved more quickly. They'll be entered in the right category later on during the approval process.
See context to find out what was said next.